ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)

Running, not enrolling

Conditions studied: Metastatic Breast Cancer

In brief

ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.

Key facts

Study ID

NCT05662345

Run by

Menarini Silicon Biosystems, INC

People needed

65

Starts

2022-12-12

Expected to finish

2026-10-01

Last updated by the study team

2026-03-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Invasive breast cancer with radiographic and/or clinical evidence of advanced metastatic or unresectable disease
• ER+/HER2- patients prior to starting 2nd line therapy or beyond OR ER/Progesterone Receptor (PR)/HER2-negative (Triple Negative) patients prior to starting any line of therapy
• Measurable and/or non-measurable disease is allowed
• Male or female breast cancer is allowed
• Age > 18 years
• Willingness to provide mandatory blood specimens
• Willing to return to enrolling institution for follow up imaging at least once

You may not qualify if…

• Life expectancy of ≤ 6 months
• Inability to provide blood samples based on the judgment of the treating provider

Where it is running

• Mayo Clinic Health System Albert Lea — Albert Lea, Minnesota, United States
• Mayo Clinic Health System Mankato — Mankato, Minnesota, United States
• Mayo Clinic — Rochester, Minnesota, United States
• MCHS Eau Claire — Eau Claire, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.